Russell Investments Group, Ltd. Savara Inc Transaction History

Russell Investments Group, Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$3.66 - $5.34 $6,602 - $9,633	1,804 Added 1466.67%	1,927 $7,000
Q1 2024 May 08, 2024	BUY	$4.19 - $5.59 $515 - $687	123 New	123 $0
Q4 2021 Jan 21, 2022	SELL	$1.04 - $1.34 $64,222 - $82,747	-61,752 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$1.18 - $1.64 $12,610 - $17,526	-10,687 Reduced 14.75%	61,752 $84,000
Q2 2021 Aug 04, 2021	SELL	$1.51 - $2.29 $265,977 - $403,369	-176,144 Reduced 70.86%	72,439 $122,000
Q1 2021 May 10, 2021	BUY	$1.17 - $2.33 $290,842 - $579,198	248,583 New	248,583 $516,000
Q4 2020 Feb 08, 2021	SELL	$1.0 - $1.47 $118,940 - $174,841	-118,940 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$1.09 - $2.21 $124,194 - $251,807	113,940 Added 2278.8%	118,940 $129,000
Q2 2020 Aug 05, 2020	BUY	$1.8 - $3.05 $9,000 - $15,250	5,000 New	5,000 $12,000

129

151M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $328M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.